Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Resectable Esophageal Squamous Cell Carcinoma
NCT07627347Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- May 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of anlotinib and bevacizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Pathological Complete Response. Started May 2026; status: recruiting.
02
Drugs
anlotinibbevacizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07627347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07627347.